1. Opioid peptides promote net intestinal absorption via two mechanism
s: stimulation of Na+ and Cl- absorption and inhibition of Cl- secreti
on. Although these transport changes are predominantly mediated by sub
mucosal neurones, it is currently unclear whether opioid peptides can
regulate enterocyte function directly. We therefore tested the hypothe
sis that enterocytes have specific opioid receptors. 2. Villus and cry
pt jejunal epithelial cells were isolated by the distended sac method
from anaesthetized guinea-pigs. Flow cytometry mras used to resolve en
terocytes from other cell types and to determine whether binding of a
fluorescently labelled opioid antagonist, naltrexone-FITC, could be pr
evented by unlabelled mu- and delta-opioid receptor agonists. A popula
tion of crypt enterocytes (similar to 21%) exhibited high-affinity nal
trexone-FITC binding to both mu- and delta-type binding sites that was
stereoselective and sodium dependent. Villus enterocytes did not exhi
bit any of these characteristics. 3. Basal cAMP production was elevate
d ill both villus and crypt cells treated with IBMX (3-isobutyl-1-meth
ylxanthine). Villus cells did not respond to 100 nM vasoactive intesti
nal peptide (VIP), nor mere they affected by opioid peptides. In contr
ast, 100 nM VIP significantly increased cAMP production in crypt epith
elial cells, which was significantly reduced by both morphiceptin and
D-Ser(2)-Leu-Enk-Thr. This opioid-mediated effect was stereoselective
and blocked by the opioid receptor antagonist naltrexone. 4. These exp
eriments suggest that enterocytes isolated from the crypt epithelium o
f guineapigs have both mu- and delta-types of opioid receptors. It is
possible that these cells participate in opioid-mediated regulation of
intestinal secretion.